TLR Therapeutics, Inc. has recently filed for an orphan drug status Phase II clinical trial with the US FDA on the treatment of myelodysplastic syndrome (MDS). About 30% of MDS cases advance to become cancer, specifically acute myeloid leukemia (AML). MDS is caused by the mutation of one or more genes that control development of blood cells. Patients with this condition usually present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Our lead drug is a therapeutic monoclonal antibody directed against the TLR2 receptor and has been in multiple clinical trials. The current global market sales of MDS drugs is USD 2.4 billion with a CAGR of approximately 10%. We expect to initiate these clinical trials in 03Q2023 and are in active discussions with corporate partners and investors. Our global joint venture partner is Neuramedy Co Ltd of Seoul, Korea and is supported multiple institutional investors as well as by the team at Berkeley Skydeck.

Leverage an existing therapeutic molecule–OPN305–that has shown early clinical promise in MDS for expansion of clinical trials and entry into a new clinical Indication–gastric cancer


Our mission is to develop and commercialize a therapeutic monoclonal antibody against TLR2 to treat patients with myelodysplastic syndrome, gastric cancer and other aggressive cancers where current therapies against TLR2 are inadequate